ADC Therapeutics (ADCT) Change in Account Payables (2023 - 2026)

ADC Therapeutics has disclosed Change in Account Payables across 4 years of filings, most recently posting -$3.9 million for Q1 2026.

• Change in Account Payables for Q1 2026 came in at -$3.9 million, down 57.42% year-over-year; the trailing twelve-month figure through Mar 2026 was -$10.5 million (down 937.42% YoY), and the FY2025 annual result was -$9.0 million, down 467.1% from the prior year.
• Change in Account Payables came in at -$3.9 million for Q1 2026 at ADC Therapeutics, down from $932000.0 in the prior quarter.
• In the past five years, Change in Account Payables ranged from a high of $6.6 million in Q4 2023 to a low of -$6.2 million in Q2 2025.
• The 4-year median for Change in Account Payables is -$1.3 million (2025), against an average of -$559769.2.
• Peak annual rise in Change in Account Payables reached 279.49% in 2024, while the deepest fall reached 262.5% in 2024.
• ADC Therapeutics' Change in Account Payables stood at $6.6 million in 2023, then sank by 44.01% to $3.7 million in 2024, then slumped by 74.67% to $932000.0 in 2025, then sank by 515.67% to -$3.9 million in 2026.
• The last three Change in Account Payables figures came in at -$3.9 million (Q1 2026), $932000.0 (Q4 2025), and -$1.3 million (Q3 2025), per Business Quant data.